博世科 reported revenue of ¥0.99B for the period ended 2026-06-30, -21.1% year on year. Net income was ¥-0.03B, a -3.3% net margin on a 15.4% gross margin. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.99B | -21.1% |
| Gross profit | ¥0.15B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.03B | — |
| Gross margin | 15.4% | Net margin -3.3% |
| Revenue Q/Q | -30.2% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.84B | 84.6% |
| R&D | ¥0.01B | 1.3% |
| SG&A | ¥0.08B | 7.6% |
| Tax & other | ¥0.01B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥8.78B |
| Total liabilities | ¥8.07B |
| Shareholders' equity | ¥0.71B |
| Equity / assets | 8.0% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | -263% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
昇辉科技 ・ 航新科技 ・ 中建环能 ・ 华智数媒 ・ 红相股份 ・ 立中集团 ・ 强力新材 ・ *ST益通 ・ 富临精工 ・ 金石亚药 ・ 中泰股份 ・ 广生堂
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies